Biotinylated Human CD24 Protein
Catalog No: CD24-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human CD24 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Ser27-Gly59 (UniProt accession: P25063-1).
Product Details
- Molecular Aliases
- CD 24; CD24 molecule; CD24A; FLJ22950; FLJ43543; MGC75043; CD24
- Protein Length
- Ser27-Gly59
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 6.5 kDa. Due to glycosylation, the protein migrates to 25-40 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human CD24 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human CD24 is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human CD24, His Tag at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-CD24 Antibody, hFc Tag with the EC50 of 5.5ng/ml determined by ELISA (QC Test).
Background
CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.
References
- Barkal AA, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019 Jul 31. doi: 10.1038/s41586-019-1456-0. D
- Sun F, Wang T, Jiang J, et al. Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design[J]. Oncotarget, 2017, 8(31):51238-51252.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.